Circulating plasmalogen levels and Alzheimer Disease Assessment Scale–Cognitive scores in Alzheimer patients
Authors:
- Paul L. WoodPWPaul L. Wood
- Rishikesh MankidyRMRishikesh Mankidy
- Shawn RitchieSRShawn Ritchie
- Doug HeathDHDoug Heath
- Julie A. WoodJWJulie A. Wood
- John FlaxJFJohn Flax
- Dayan B. GoodenoweDGDayan B. Goodenowe
- 1 January 2010
- journal article
- Published by Canadian Science Publishing in Journal of Psychiatry and Neuroscience
- Vol. 35 (1) , 59-62
Abstract
Plasmalogens, which are key structural phospholipids in brain membranes, are decreased in the brain and serum of patients with Alzheimer disease (AD). We performed this pilot study to evaluate the relation between the levels of circulating plasmalogens and Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) scores in patients with AD. We evaluated participants' ADAS-Cog scores and serum plasmalogen levels. For the 40 included AD patients with an ADAS-Cog score between 20 and 46, were tested their ADAS-Cog score 1 year later. The levels of docosahexaenoic acid plasmalogen were measured by use of liquid chromatography-tandem mass spectrometry. We found that the ADAS-Cog score increased significantly in AD patients with circulating plasmalogen levels that were 75%). This was a pilot study with 40 patients, and the results require validation in a larger population. Our study demonstrates that decreased levels of plasmalogen precursors in the central nervous system correlate with functional decline (as measured by ADAS-Cog scores) in AD patients. The use of both ADAS-Cog and serum plasmalogen data may be a more accurate way of predicting cognitive decline in AD patients, and may be used to decrease the risk of including patients with no cognitive decline in the placebo arm of a drug trial.Keywords
This publication has 31 references indexed in Scilit:
- Atrophy Measurement of the Anterior Commissure and Substantia Innominata with 3T High-Resolution MR Imaging: Does the Measurement Differ for Patients with Frontotemporal Lobar Degeneration and Alzheimer Disease and for Healthy Subjects?American Journal of Neuroradiology, 2008
- Effects of cholesterol levels on the excitability of rat hippocampal neuronsMolecular Membrane Biology, 2008
- Decreased white matter lesion volume and improved cognitive function after liver transplantationHepatology, 2007
- Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imagingNeurology, 2006
- Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometryJournal of Neurochemistry, 2001
- Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disordersThe American Journal of Clinical Nutrition, 2000
- Isolation of a Chinese hamster fibroblast variant defective in dihydroxyacetonephosphate acyltransferase activity and plasmalogen biosynthesis: use of a novel two-step selection protocolBiochemical Journal, 1998
- Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brainBrain Research, 1995
- Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, α2-macroglobulin and C-reactive proteinBrain Research, 1993
- Metabolism of chimyl alcohol and phosphatidyl ethanolamine in the rat brainLipids, 1968